Indications for: BREXAFEMME
≥18yrs or post-menarchal: 300mg orally every 12hrs for 1 day. Concomitant strong CYP3A4 inhibitors: 150mg orally every 12hrs for 1 day.
<18yrs or pre-menarchal: not established.
Severe hepatic impairment: not studied. Risk of fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 4 days after the last dose. Exclude pregnancy status prior to initiation. Nursing mothers.
Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole); reduce ibrexafungerp dose. May be antagonized by strong or moderate CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin, St. John’s wort, long acting barbiturates, bosentan, efavirenz, etravirine); avoid concomitant use.
Diarrhea, nausea, abdominal pain, dizziness, vomiting.
Generic Drug Availability: